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OBJECTIVES We sought to ascertain the prevalence and mode of expression of familial disease in a
consecutive series of patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia
(ARVC/D).
BACKGROUND Autosomal-dominant inheritance is recognized in ARVC. The prevalence and mode of
expression of familial disease in consecutive, unselected families is uncertain.
METHODS First- and second-degree relatives of 67 ARVC index patients underwent cardiac evaluation
with history and examination, 12-lead and signal-averaged electrocardiogram (ECG),
two-dimensional and Doppler echocardiography, metabolic exercise testing and Holter
monitoring. Diagnoses were made in accordance with published criteria.
RESULTS Of 298 relatives, 29 (10%; mean age 37.4  16.4 years) had ARVC. These were from 19 of
the 67 families, representing familial involvement in 28%. Of these affected relatives, 72%
were asymptomatic, 17% had ventricular tachycardia (sustained VT 10%, nonsustained VT
7%) and 21% had left ventricular involvement. A further 32 relatives (11%; 37.7 12.4 years)
exhibited nondiagnostic ECG, echocardiographic or Holter abnormalities. Fifteen of these
relatives were from families with only the proband affected, and inclusion of this subset of
relatives would have resulted in familial ARVC in 48% of index cases. Four additional
relatives (1% to 3%) fulfilled diagnostic criteria for dilated cardiomyopathy without any
features of right ventricular disease.
CONCLUSION By using current diagnostic criteria, familial disease was present in 28% of index patients. A
further 11% of their relatives had minor cardiac abnormalities, which, in the context of a
disease whose mode of inheritance is autosomal dominant, are likely to represent early or mild
disease expression. We advocate that the current ARVC diagnostic criteria are modified to
reflect the broader spectrum of disease that is observed in family members. (J Am Coll
Cardiol 2002;40:1445–50) © 2002 by the American College of Cardiology Foundation
Arrhythmogenic right ventricular cardiomyopathy/dysplasia
(ARVC/D) is a disease of the right ventricle characterized
by fibrofatty replacement of the myocardium (1). Although
clinical genetic studies have indicated that the disease may
be autosomal-dominantly inherited with age-related and
variable penetrance (2), only a small number of disease-
causing mutations have as yet been identified (3,4).
To facilitate the clinical diagnosis of ARVC, an interna-
tional task force has proposed a series of diagnostic criteria
based on electrocardiographic and morphologic features (5).
Theoretically, the same criteria might be used to identify
relatives who also have ARVC; however, the experience of
similar criteria in diagnosing hypertrophic (6) and dilated
cardiomyopathies (7) has shown that many relatives have
phenotypic abnormalities that, although “nondiagnostic,”
are nevertheless indicative of disease. The aim of this study
was to determine the prevalence of cardiac abnormalities in
the relatives of a large population of consecutively referred
patients with ARVC to estimate the prevalence of familial
disease and to evaluate the utility of the published diagnostic
criteria in family screening.
METHODS
Diagnostic criteria. Index ARVC cases and their relatives
were evaluated in accordance with criteria defined by a task
force of the European Society of Cardiology and Interna-
tional Society and Federation of Cardiology (5). The task
force criteria rely on the demonstration of right ventricular
structural and functional features, depolarization/
repolarization electrocardiographic abnormalities, demon-
stration of arrhythmias originating from the right ventricle,
fibrofatty infiltration of the right ventricular myocardium
and evidence of familial disease. The criteria are subdivided
into major and minor features, major criteria being abnor-
malities deemed more specific for ARVC. A combination
of: 1) two major, 2) one major plus two minor, or 3) four
minor features are consistent with a positive diagnosis of
ARVC. Relatives were categorized into three groups after
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cardiac evaluation. Those fulfilling the task force diagnostic
criteria for ARVC were labeled as affected relatives. Rela-
tives with an isolated, minor ARVC criterion were labeled
as having probable ARVC. Relatives without any features of
disease were considered unaffected. Dilated cardiomyopathy
was diagnosed according to World Health Organization
criteria (1). Left ventricular (LV) enlargement was defined
as a left ventricular end-diastolic dimension (LVEDD) of
112% predicted value corrected for age and body surface
area (8). Functional impairment of the LV was diagnosed
when a depressed fractional shortening of 25% was
present but with cavity dimensions within the predicted
range.
Probands. At St. George’s Hospital Medical School there
has been an ongoing program of evaluating families of
patients diagnosed with primary cardiomyopathies. Since
1990, 75 index patients that have fulfilled the task force
criteria for ARVC have been evaluated. These patients were
referred from the Department of Clinical Cardiology and
secondary care centers. Postmortem cases (with fibrofatty
replacement of the right ventricular myocardium) were also
included.
Relatives. A detailed pedigree of the family of each index
patient was assembled, and permission was sought to invite
first-degree relatives (parents, siblings and children) and,
where appropriate, second-degree relatives for cardiovascu-
lar evaluation. Probands and family members were coun-
seled by specialist nurses before the cardiac evaluation.
Ethical approval for the study was obtained from the Local
Research Ethics Committee.
Cardiac evaluation. After obtaining informed consent,
relatives underwent history and clinical examination, 12-
lead electrocardiogram (ECG), signal-averaged electrocar-
diography (SAECG), two-dimensional trans-thoracic and
Doppler echocardiography, 24-h Holter monitoring and
maximal upright cardiopulmonary exercise testing. Blood
was taken and stored for future genetic studies after in-
formed consent.
Historical evaluation. This evaluation involved the sub-
jective assessment of cardiac symptoms. Palpitations were
defined as an awareness of the heart beating faster or harder.
Syncope was defined as an episode of sudden onset loss of
consciousness with spontaneous recovery. Presyncope was
defined as the sensation of impending loss of consciousness
associated with the feeling of dizziness or lightheadedness.
Echocardiography. Two-dimensional and Doppler echo-
cardiography was performed using an Acuson 128 XP/10
(Mountain View, California), GE Vingmed system V (GE
Ultrasound Europe, Horten, Norway) or a Hewlett-Packard
Sonos 1000 (Hewlett-Packard, Andover, Massachusetts) by
experienced hospital technicians in an outpatient setting.
Standard views for M-mode and two-dimensional studies
were obtained, and conventional techniques were used for
assessing the left atrium and ventricle (9). Evaluation of
structural and functional abnormalities of the right atrium
and right ventricle (RV) was undertaken using an estab-
lished protocol (10). This involved assessment of the RV for
local or global dilation and reduced function as well as wall
motion abnormalities (hypokinesia, akinesia and dyskinesia)
and aneurysms.
SAECG. The SAECG was performed using a MAC VU
(Marquette Electronics Inc., Diagnostic Division, Milwau-
kee, Wisconsin). Time domain analysis was obtained in the
bandpass filter 40 to 250 Hz with the following parameters
evaluated: filtered QRS interval duration, low-amplitude
signal duration and root mean square (RMS) of the voltage
in the last 40 ms of the filtered QRS (RMS40). The signal
averaged ECG was considered positive for late potentials
when at least two of the following parameters were abnor-
mal: filtered QRS duration 114 ms, low-amplitude signal
duration 38 ms and RMS40 20 V (11). Patients with
bundle branch block were excluded from time-domain
analysis.
Ambulatory ECG monitoring. Twenty-four hour ambu-
latory monitoring was performed during unrestricted daily
activities using the Marquette Holter recording system on
two channels (Marquette Electronics Inc., Diagnostic Di-
vision). Computer-assisted analysis was performed using the
Marquette series 8000 laser Holter and laser Holter XP
system. The frequency of ventricular ectopy and its mor-
phology was noted. Nonsustained ventricular tachycardia
(NSVT) was defined as a run of three or more consecutive
beats at a rate of 120 beats/min, lasting 30 s and
sustained VT defined as a consecutive run of beats 30 s.
Exercise testing. Exercise testing was performed in the
upright position on a Sensormedics ergometrics 800 S cycle
ergometer (Ergoline, Bitz, Germany), using a ramp protocol
ranging from 10 to 15 W/min (selected to ensure adequate
stress and avoid premature fatigue) in a quiet air-
conditioned room with an average temperature of 21°C and
full resuscitation facilities. An experienced cardiologist,
nurse and senior technician supervised each test. Before the
test all relatives underwent a 3-min practice run at zero work
rate.
Endomyocardial biopsies. Biopsies were initially per-
formed as part of the assessment of eight index patients and
three relatives. They were discontinued as a routine part of
evaluation because sampling error has been shown to occur
as a result of the segmental nature of the disease, and the
Abbreviations and Acronyms
ARVC/D  arrhythmogenic right ventricular
cardiomyopathy/dysplasia
FS  fractional shortening
LBBB  left bundle branch block
LV  left ventricle
LVEDD  left ventricular end-diastolic diameter
NSVT  nonsustained ventricular tachycardia
RV  right ventricle
SAECG  signal-averaged electrocardiography
SCD  sudden cardiac death
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septum, which is sampled in preference to the right ven-
tricular free wall for safety reasons, is relatively spared in
ARVC (12,13).
Statistical analysis. Continuous variables are expressed as
mean value  1 SD. Discrete variables are shown as
percentages. Chi-squared analysis was used to test for
associations between dichotomous variables. With continu-
ous variables, group means were compared with the un-
paired Student t or Mann-Whitney U test if the variable did
not fulfill the normality assumption. A value of p  0.05
was considered statistically significant. All data were ana-
lyzed using the Statistical Package for Social Sciences
(SPSS, version 9.0).
RESULTS
Index patients. Of 75 consecutive index patients (age 31
11.4 years, range 11 to 60 years), presentation with sudden
cardiac death (SCD) occurred in 44 (59%), with a diagnosis
established at autopsy. The majority of live and SCD index
patients were male (21/31, or 68% and 29/44, or 66%,
respectively; Table 1) . The SCD individuals presented at a
younger age than the live patients (age 27.9  9.2 vs. 35.3
 13.1 years; p  0.05). Six (14%) of the deceased patients
had experienced syncope during the month before their
death. All 31 of the live patients presented with cardiac
symptoms: 10 (32%; 46 12 years) presented with syncope,
2 (6.5%; 26 and 38 years) with aborted SCD secondary to
ventricular fibrillation, 17 (55%; 37.6  11.2 years) with
palpitation/presyncope (8 with palpitations only and none
with presyncope) and 2 (6.5%; 18 and 60 years) with heart
failure. Ventricular tachycardia (VT) of left bundle block
(LBBB) morphology had been documented in 29 (94%) of
the 31 live patients (monomorphic sustained VT in 20, or
65%, and, NSVT in 9, or 29%). One index patient from the
live group died during the study period at age 21, 3 years
after diagnosis. This patient had declined an automatic
internal cardioverter defibrillator after syncopal episodes and
sustained ventricular tachycardia were documented. LV
involvement was detected in six (19%; 33  16.4 years) live
cases (LVEDD 58.5  9.1 mm, fractional shortening [FS]
20.6  8.1%). One of the patients presenting with heart
failure underwent cardiac transplantation at age 28, 10 years
after the initial diagnosis.
Relatives. The families of 67 of the 75 index cases with
ARVC consented to cardiac evaluation. Of the remaining
eight, four families were not residing in the United King-
dom and so were unavailable for cardiac evaluation, and four
families did not wish to undergo assessment. The total
number of relatives who underwent cardiac evaluation was
298 (4.4  4 per family). Their mean age was 35.5  17.9
years, 45% were males and 194 (65%) were first-degree
relatives.
Affected relatives. Twenty-nine relatives (10%; 37.4 
16.4 years) fulfilled the task force criteria for ARVC (Table
1). These affected relatives were from 19 of the 67 families
evaluated; thus, familial involvement was present in 28% of
index cases. No single family demonstrated a significantly
increased number of affected relatives, the largest number
being three in two families. Two of the affected relatives had
already been diagnosed with ARVC before attending our
institution, after presentation to their local hospitals with
sustained monomorphic VT. Twenty-one (72%) of these
were male. The prevalence of individual task force criteria
are shown in Table 2. Ventricular arrhythmias were ob-
served in 15 (52%). VT of LBBB morphology was docu-
mented in five (17%) and were all males aged 34.8  2.9
years. There was no association between age or a positive
SAECG and the occurrence of VT. Analysis of the diag-
nostic criteria among index patients and affected relatives
did not demonstrate a specific intrafamilial phenotype (i.e.,
the presence of a particular electrocardiographic or echocar-
diographic abnormality did not run through a family).
Relatives with probable ARVC. Thirty-two (11%, 37.7
12.4 years) relatives (Table 1) had isolated, minor criteria
detectable on cardiac evaluation, of which 23 (72%) were
female. There was no segregation of cases within any one
family. There was no significant difference in age between
this subgroup of relatives and the live index patients or
affected relatives. Fifteen of these probable ARVC patients
were from 13 families in whom only the index patient was
affected. Inclusion of these probable ARVC relatives re-
sulted in a familial prevalence of ARVC in 48% of index
cases. The most frequent criteria in this group were elec-
trocardiographic with T-wave inversion in 13 (41%) and a
positive SAECG in 10 (31%). One female relative (3%),
aged 36, had documented NSVT on Holter monitoring
(Table 1). A further 10 (3%) of the total relatives had 100
ectopics of LBBB morphology recorded on Holter moni-
toring over 24 h, with seven (2%) of these having 200
ectopics over that period.
LV abnormalities. LV involvement in the absence of any
other cardiac disease was present in 6 (21%) affected
relatives (39.2  14.2 years; five males) with LV dilation in
Table 1. Clinical Characteristics of Index Patients, Affected
Relatives and Relatives With Probable ARVC
Deceased
Index
Patients
Live
Index
Patients
Affected
Relatives
Probable
ARVC
Number in category 44 31 29 32
Age (yrs) 27.9  9.2 35.3  13.1 37.4  16.4 37.7  12.4
Male:female (%) 66:34 68:32 72:28 28:72
Cardiac symptoms – 31 (100%) 8 (28%) 5 (16%)
Palpitations – 25 (81%) 6 (21%) 5 (16%)
Presyncope – 15 (48%) 1 (3%) 0
Syncope 6 (14%)* 12 (39%) 3 (10%) 0
NSVT – 9 (29%)† 2 (7%) 1 (3%)
Sustained VT – 20 (64%) 3 (10%) 0
Evidence of LV
involvement
– 6 (19%) 6 (21%) 0
*Episode of syncope within 1 month of death. †Index cases demonstrating only
NSVT. (%) Represents percentage value within each subgroup.
ARVC  arrhythmogenic right ventricular cardiomyopathy; LV  left ventricle;
NSVT  nonsustained ventricular tachycardia; VT  ventricular tachycardia.
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three and depressed fractional shortening in three (mean
LVEDD 56.2  3.4 mm, FS 24.1  7.6%). There was no
significant difference in age between those affected relatives
with LV involvement and those with normal LV function.
An additional four (1% to 3%) relatives (three males, one
female, 46  12 years) from three families had dilated
cardiomyopathy (mean LVEDD 64 2 mm, mean FS 17.6
 5.5%). Two had previously presented to hospital with
symptoms of heart failure. RV structural or functional
abnormalities were absent, and no ventricular tachycardias
were documented in this group.
In summary, 61 (21%) of 298 relatives demonstrated at
least one minor criterion from the task force criteria after
cardiac evaluation, and a further four (1% to 3%) had dilated
cardiomyopathy (Table 3).
DISCUSSION
Prevalence of familial ARVC and mode of disease ex-
pression. This is the first study to prospectively determine
the prevalence of cardiovascular abnormalities in the rela-
tives of consecutive, index ARVC patients. The application
of published task force diagnostic criteria demonstrated
evidence of ARVC in 28% of families. When all cardiovas-
cular abnormalities, including LV involvement were consid-
ered, 48% had evidence for familial disease. This suggests
that familial disease is common and that the spectrum of
disease is wider than previously thought. Several studies
have evaluated cardiovascular abnormalities in relatives, but
these have been performed in selected families (14) or in
small numbers of probands (15). As a result, the prevalence
of familial ARVC has until now only been an estimate
(2,5,16).
As in previous studies, the phenotypic features of ARVC
in this study were more common in males, with females
representing less than one-third of the affected relatives
(17,18). The average age at diagnosis was 37.4 (16.4)
years, but because the majority were asymptomatic, the time
of phenotypic disease expression cannot be accurately de-
fined. The male predominance in this disease remains
Table 2. Task Force Criteria Present in Live Index Patients, Affected and Probable Affected Relatives
Diagnostic Criteria
Live Index Patients
(n  31)
Affected Relatives
(n  29)
Relatives with
Probable ARVC
(n  32)
Family history
Confirmed at necropsy or surgery – 27 (93) 26 (81)
Premature sudden death (35 years) caused by suspected ARVC 9 (29) 7 (24) 5 (16)
Clinical diagnosis based on present criteria – – –
ECG depolarization/conduction abnormalities
Epsilon waves 1 (3) 0 (0) 0 (0)
Localized prolongation (>110 ms) of the QRS complex (V1–V3) 6 (19) 7 (24) 0 (0)
Late potentials seen on signal averaged ECG 18 (58) 23 (79) 10 (31)
Repolarization abnormalities
Inverted T waves in right precordial leads (V2 and V3) 20 (64) 13 (45) 13 (41)
Tissue characterization of walls
Fibrofatty replacement of myocardium on endomyocardial biopsy 2/8 0/2 0/1
Global and/or regional dysfunction and structural alterations
Severe dilatation and reduction of RVEF with no (or only mild)
LV impairment
14 (45) 1 (3) 0 (0)
Localized RV aneurysms 3 (10) 0 (0) 0 (0)
Severe segmental dilatation of the RV 1 (3) 0 (0) 0 (0)
Mild global RV dilatation and/or EF reduction with normal LV 8 (26) 11 (38) 1 (3)
Mild segmental dilation of the RV 0 (0) 3 (10) 0 (0)
Regional RV hypokinesia 1 (3) 3 (10) 3 (9)
Arrhythmias
LBBB type VT (sustained or non-sustained) on: ECG 18 (58) 1 (3) 0 (0)
Holter monitoring 6 (19) 2 (7) 1 (3)
During exercise testing 6 (19) 2 (7) 0 (0)
Frequent ventricular extrasystoles (more than 1,000/24 h) on Holter monitoring 13 (42) 11 (38) 2 (6)
Numbers in parentheses indicate the percentage within each group. Major ARVC Task Force diagnostic criteria are shown in bold.
ARVC  arrhythmogenic right ventricular cardiomyopathy; ECG  electrocardiogram; LBBB  left bundle branch block; LV  left ventricle; RV  right ventricle;
RVEF  right ventricular ejection fraction.
Table 3. Cardiovascular Abnormalities Detected on Evaluation
of Relatives
ARVC Criteria
Number of
Relatives (%)
Abnormal ECG 31 (10.4)
Abnormal signal-averaged ECG 33 (11.1)
RV abnormalities on echocardiogram 22 (7.4)
Ectopy 1,000/24 h 13 (4.4)
Ventricular tachycardia 6 (2)
Dilated cardiomyopathy 4 (1.3)
Total number of relatives with abnormalities
on investigation
65 (22)
Total number relatives  298.
ARVC arrythmogenic right ventricular cardiomyopathy; ECG epsilon waves,
localized prolongation of the QRS complex (V1–V3) and T-wave inversion in the
right precordial leads; VT  sustained or non-sustained ventricular tachycardia;
RV  right ventricle.
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unexplained, particularly as ARVC is autosomally inherited,
although interestingly, the probable ARVC group consisted
predominantly of females (72%). This may represent
gender-related incomplete penetrance or indicate that ad-
ditional environmental/genetic factors maybe necessary for
complete disease expression. X-linked disease has not been
reported, and examination of our pedigrees did not support
this mode of inheritance.
Task force diagnostic criteria in the context of familial
ARVC. During the evaluation of families, a significant
proportion of relatives (11%) were found to have isolated,
minor cardiac abnormalities that did not fulfill the task force
criteria for a diagnosis of ARVC. This group was labeled as
having probable ARVC. The most common findings were
electrocardiographic with T-wave inversion in the right
precordial leads in 41%, positive SAECGs in 31% and
NSVT documented in 3%. Structural or functional RV
abnormalities were uncommon and observed only in 12% of
these relatives. Given that the mode of disease inheritance is
autosomal dominant, ECG abnormalities in first-degree
relatives are likely to represent early disease or mild cardio-
myopathy. If this were the case, it would suggest a much
higher prevalence of familial ARVC than previously
thought. This would be analogous to the findings of isolated
LV enlargement or reduced fractional shortening observed
in relatives of patients with familial dilated cardiomyopathy
(7) and the presence of electrocardiographic and mild
echocardiographic abnormalities observed in first-degree
relatives in hypertrophic cardiomyopathy (6). An important
implication of this study is that there is a subset of relatives
who are not recognized by the present diagnostic criteria.
The task force criteria were designed to help standardize the
diagnosis of ARVC. The criteria were reached by expert
consensus opinion, based primarily on tertiary center expe-
rience with symptomatic index cases with sustained arrhyth-
mias and information derived from patients presenting with
SCD. As a consequence, the criteria are highly specific but
presently lack sensitivity when evaluating asymptomatic
patients and relatives with incomplete expression. Their
application in the evaluation of familial disease may there-
fore lead to the underestimation of true disease prevalence.
For example, the presence of 1,000 extrasystoles/24 h is
designated as a minor criterion, but this figure is arbitrary
and based on a more severely affected index group. It is
probable that ventricular ectopy of 200 or more extrasystoles
observed in a proportion of our relatives represents a
manifestation of underlying disease. We therefore advocate
that the present diagnostic criteria should be modified in
recognition of a broader spectrum of familial disease expres-
sion. We propose that in the context of proven ARVC, a
first-degree relative with a positive SAECG, or a minor
ECG, Holter or echocardiographic abnormality from the
present diagnostic criteria should indicate familial involve-
ment (Table 4). In addition, we advocate that the frequency
of ectopic activity accepted as a marker of disease expression
should be reduced from 1,000 to 200 extrasystoles over a
24-h period. The modification of the diagnostic criteria will
hopefully assist in the correct classification of affected family
members, which is of vital importance for genetic analyses
aimed at identifying linkage to a particular locus as well as
help to identify those who are potentially at risk from
serious arrhythmic events. Ultimately, only the advent of
genetic testing for familial ARVC will allow the true
interpretation of these abnormalities and provide the gold
standard for diagnosis.
Study limitations. Cardiac evaluation of all first-degree
family members was not performed in all families either
because of family members being unavailable or unwilling to
undergo testing; thus, complete ascertainment was not
obtained, which predisposes toward the underreporting of
familial disease. With regards to the investigative tests, the
assessment for structural and functional abnormalities of the
RV highlights the weakest aspect of the present diagnostic
tests. Despite the well-recognized difficulties in imaging the
RV, transthoracic echocardiography remains the first-line
imaging modality because it is noninvasive and can be used
for serial assessments. However, it is unable to characterize
tissue, and subtle wall motion abnormalities may not be
detected. Cardiac magnetic resonance offers the potential
for improved imaging of the RV but at the present time is
not routinely used because of cost and specificity concerns
(19,20).
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Table 4. Proposed Modification of Task Force Criteria for the
Diagnosis of Familial ARVC
ARVC in First-Degree Relative Plus One of the Following:
1. ECG T-wave inversion in right precordial leads
(V2 and V3)
2. SAECG Late potentials seen on signal-averaged ECG
3. Arrhythmia LBBB type VT on ECG, Holter monitoring
or during exercise testing
Extrasystoles 200 over a 24-h period*
4. Structural or functional
abnormality of the RV
Mild global RV dilatation and/or EF
reduction with normal LV
Mild segmental dilatation of the RV
Regional RV hypokinesia
*Previously 1,000/24-h period in task force criteria.
ARVC  arrythmogenic right ventricular cardiomyopathy; ECG  electrocar-
diogram; EF  ejection fraction; LBBB  left bundle branch block; RV  right
ventricle; SAECG  signal-averaged electrocardiography; VT  ventricular tachy-
cardia.
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